CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Summary

This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that have not responded to chemotherapy medications (chemorefractory). Metabolism is how the cells in the body use molecules (carbohydrates, fats, and proteins) from food to get the energy they need to grow, reproduce and stay healthy.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Advanced Biliary Tract Carcinoma
• Advanced Colorectal Carcinoma
• Advanced Gastroesophageal Junction Adenocarcinoma
• Advanced Lung Adenocarcinoma
• Advanced Malignant Solid Neoplasm
• Advanced Ovarian Carcinoma
• Advanced Pancreatic Carcinoma
• Advanced Urothelial Carcinoma
• Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
• Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
• Metastatic Biliary Tract Carcinoma
• Metastatic Colorectal Carcinoma
• Metastatic Gastroesophageal Junction Adenocarcinoma
• Metastatic Lung Adenocarcinoma
• Metastatic Ovarian Carcinoma
• Metastatic Pancreatic Carcinoma
• Metastatic Urothelial Carcinoma
• Refractory Biliary Tract Carcinoma
• Refractory Colorectal Carcinoma
• Refractory Gastroesophageal Junction Adenocarcinoma
• Refractory Lung Adenocarcinoma
• Refractory Ovarian Carcinoma
• Refractory Pancreatic Carcinoma
• Refractory Urothelial Carcinoma
• Stage II Pancreatic Cancer AJCC v8
• Stage III Colorectal Cancer AJCC v8
• Stage III Lung Cancer AJCC v8
• Stage III Ovarian Cancer AJCC v8
• Stage III Pancreatic Cancer AJCC v8
• Stage IV Colorectal Cancer AJCC v8
• Stage IV Lung Cancer AJCC v8
• Stage IV Ovarian Cancer AJCC v8
• Stage IV Pancreatic Cancer AJCC v8

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Northwestern University

Last updated on ClinicalTrials.gov

March 10, 2023

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites